<VariationArchive VariationID="2751589" VariationName="NM_000532.5(PCCB):c.1353_1356del (p.Asn452fs)" VariationType="Deletion" Accession="VCV002751589" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2024-02-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2908885" VariationID="2751589">
      <GeneList>
        <Gene Symbol="PCCB" FullName="propionyl-CoA carboxylase subunit beta" GeneID="5096" HGNC_ID="HGNC:8654" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="136250340" stop="136330169" display_start="136250340" display_stop="136330169" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="135969166" stop="136049012" display_start="135969166" display_stop="136049012" Strand="+" />
          </Location>
          <OMIM>232050</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000532.5(PCCB):c.1353_1356del (p.Asn452fs)</Name>
      <CanonicalSPDI>NC_000003.12:136327684:ACCAAC:AC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3q22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="136327685" stop="136327688" display_start="136327685" display_stop="136327688" variantLength="4" positionVCF="136327684" referenceAlleleVCF="TACCA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="136046527" stop="136046530" display_start="136046527" display_stop="136046530" variantLength="4" positionVCF="136046526" referenceAlleleVCF="TACCA" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>N452fs</ProteinChange>
      <ProteinChange>N472fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.136046529_136046532del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.136046529_136046532del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.136327687_136327690del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.136327687_136327690del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008939.1" sequenceAccession="NG_008939" sequenceVersion="1" change="g.82363_82366del">
            <Expression>NG_008939.1:g.82363_82366del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000532.5" sequenceAccession="NM_000532" sequenceVersion="5" change="c.1353_1356del" MANESelect="true">
            <Expression>NM_000532.5:c.1353_1356del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000523.2" sequenceAccession="NP_000523" sequenceVersion="2" change="p.Asn452fs">
            <Expression>NP_000523.2:p.Asn452fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001178014.2" sequenceAccession="NM_001178014" sequenceVersion="2" change="c.1413_1416del">
            <Expression>NM_001178014.2:c.1413_1416del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001171485.1" sequenceAccession="NP_001171485" sequenceVersion="1" change="p.Asn472fs">
            <Expression>NP_001171485.1:p.Asn472fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000532.5(PCCB):c.1353_1356del (p.Asn452fs) AND Propionic acidemia" Accession="RCV003511748" Version="1">
        <ClassifiedConditionList TraitSetID="3247">
          <ClassifiedCondition DB="MedGen" ID="C0268579">Propionic acidemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-08-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11136555</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24059531</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27227689</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3247" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5805" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Propionic acidemia</ElementValue>
                <XRef ID="Propionic+acidemia/5994" DB="Genetic Alliance" />
                <XRef ID="HP:0003571" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0011628" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycinemia, ketotic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperglycinemia with ketoacidosis and leukopenia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ketotic hyperglycinemia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PROP</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="467" />
                <XRef ID="467" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of propionic acidemia (PA) ranges from neonatal-onset to late-onset disease. Neonatal-onset PA, the most common form, is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis and management, this is followed by progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death. It is frequently accompanied by metabolic acidosis with anion gap, lactic acidosis, ketonuria, hypoglycemia, hyperammonemia, and cytopenias. Individuals with late-onset PA may remain asymptomatic and suffer a metabolic crisis under catabolic stress (e.g., illness, surgery, fasting) or may experience a more insidious onset with the development of multiorgan complications including vomiting, protein intolerance, failure to thrive, hypotonia, developmental delays or regression, movement disorders, or cardiomyopathy. Isolated cardiomyopathy can be observed on rare occasion in the absence of clinical metabolic decompensation or neurocognitive deficits. Manifestations of neonatal and late-onset PA over time can include growth impairment, intellectual disability, seizures, basal ganglia lesions, pancreatitis, and cardiomyopathy. Other rarely reported complications include optic atrophy, hearing loss, premature ovarian insufficiency, and chronic renal failure.</Attribute>
                <XRef ID="NBK92946" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">22593918</ID>
                <ID Source="BookShelf">NBK92946</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="GMDI/SERN, 2017">
                <URL>https://managementguidelines.net/guidelines.php/104/PROP%20Nutrition%20Guidelines/Version%201.2</URL>
                <CitationText>PROP Nutrition Management Guidelines</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Propionic and Methylmalonic Acidemia: C3 Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="35" DB="Orphanet" />
              <XRef ID="C0268579" DB="MedGen" />
              <XRef ID="MONDO:0011628" DB="MONDO" />
              <XRef Type="MIM" ID="606054" DB="OMIM" />
              <XRef Type="primary" ID="HP:0003571" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8000509" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="26507701|MedGen:C0268579" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004314484" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11136555</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24059531</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27227689</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PCCB protein in which other variant(s) (p.Arg514*) have been determined to be pathogenic (PMID: 11136555, 24059531, 27227689). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with PCCB-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change results in a frameshift in the PCCB gene (p.Asn452Metfs*98). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 88 amino acid(s) of the PCCB protein and extend the protein by 9 additional amino acid residues.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PCCB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.136046527_136046530del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268579" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8000509" TraitType="Disease" MappingType="XRef" MappingValue="C0268579" MappingRef="MedGen">
        <MedGen CUI="C0268579" Name="Propionic acidemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

